                         SEQUENCE LISTING

<110>  Beijing Xuanyi PharmaSciences Co., Ltd.
 
<120>  PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF

<130>  CSPL-008/01WO 332638-2065

<150>  US 62/908,435
<151>  2019-09-30

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  132
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  recombinant IL-2

<400>  1

Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu 
1               5                   10                  15      


Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn 
            20                  25                  30          


Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys 
        35                  40                  45              


Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro 
    50                  55                  60                  


Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg 
65                  70                  75                  80  


Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys 
                85                  90                  95      


Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr 
            100                 105                 110         


Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile 
        115                 120                 125             


Ser Thr Leu Thr 
    130         


<210>  2
<211>  402
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  recombinant IL-2

<400>  2
atgccaacct cctcctctac caagaaaact caactgcaac tggaacacct gctgctggat       60

ctgcaaatga ttctgaacgg cattaacaac tacaagaacc cgaaactgac ccgtatgctg      120

accttcaaat tctatatgcc gaagaaagct accgaactga aacacctgca atgcctggaa      180

gaggagctga aaccgctgga ggaggttctg aacctggctc agagcaagaa ctttcatctg      240

cgtccacgtg acctgatttc caacatcaac gttatcgttc tggaactgaa aggtagcgaa      300

accactttca tgtgcgagta cgctgacgaa accgctacca tcgttgaatt tctgaaccgc      360

tggatcacct tctctcagtc cattatctct actctgacct aa                         402


<210>  3
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  recombinant IL-2

<400>  3

Met Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His 
1               5                   10                  15      


Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys 
            20                  25                  30          


Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys 
        35                  40                  45              


Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys 
    50                  55                  60                  


Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu 
65                  70                  75                  80  


Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu 
                85                  90                  95      


Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala 
            100                 105                 110         


Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile 
        115                 120                 125             


Ile Ser Thr Leu Thr 
    130             


<210>  4
<211>  32
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  forward primer

<400>  4
aatcatatgg cacctacttc aagttctaca aa                                     32


<210>  5
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  reverse primer

<400>  5
aatttatcaa gttagtgttg agatgat                                           27


